Mar 03, 2022 / 09:30AM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Allergy Therapeutics interim results. (Operator Instructions) I would like to remind all participants that this call is being recorded.
And now let me hand it over to the CEO of Allergy Therapeutics, Manuel Llobet, to open the presentation. Please go ahead.
Manuel Llobet - Allergy Therapeutics plc - CEO & Executive Director
Thank you very much, and good morning, everyone, and many thanks for joining us today for Allergy Therapeutics interim results for the 6 months ended December 2021. Joining me today are 2 people that you know well, Nick Wykeman, our Chief Financial Officer; and Alan Bullimore, our Head of Business Innovation.
As you can see here in this slide, maintaining focus for a pivotal year ahead, this is really a pivotal year. It has taken us a lot of effort, investment, energy and passion to reach this year where 2 pivotal studies that can be transformational for the company are taking place. We will give you more details of these studies during the presentation.
And
Q4 2021 Allergy Therapeutics PLC Earnings Call Transcript
Mar 03, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers